Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 253

1.

Defining EGFR amplification status for clinical trial inclusion.

French PJ, Eoli M, Sepulveda JM, de Heer I, Kros JM, Walenkamp A, Frenel JS, Franceschi E, Clement PM, Weller M, Ansell P, Looman J, Bain E, Morfouace M, Gorlia T, van den Bent M.

Neuro Oncol. 2019 May 24. pii: noz096. doi: 10.1093/neuonc/noz096. [Epub ahead of print]

PMID:
31125418
2.

Elusive Neurotoxicity in T Cell-Boosting Anticancer Therapies.

Zheng PP, Kros JM, Wang G.

Trends Immunol. 2019 Apr;40(4):274-278. doi: 10.1016/j.it.2019.02.005. Epub 2019 Mar 12.

PMID:
30876815
3.

Clinical evaluation of a dedicated next generation sequencing panel for routine glioma diagnostics.

Synhaeve NE, van den Bent MJ, French PJ, Dinjens WNM, Atmodimedjo PN, Kros JM, Verdijk R, Dirven CMF, Dubbink HJ.

Acta Neuropathol Commun. 2018 Nov 23;6(1):126. doi: 10.1186/s40478-018-0633-y.

4.

Comparative proteomic analysis of cat eye syndrome critical region protein 1- function in tumor-associated macrophages and immune response regulation of glial tumors.

Zhu C, Mustafa DAM, Krebber MM, Chrifi I, Leenen PJM, Duncker DJ, Dekker L, Luider TM, Kros JM, Cheng C.

Oncotarget. 2018 Sep 11;9(71):33500-33514. doi: 10.18632/oncotarget.26063. eCollection 2018 Sep 11.

5.

The complement system in glioblastoma multiforme.

Bouwens van der Vlis TAM, Kros JM, Mustafa DAM, van Wijck RTA, Ackermans L, van Hagen PM, van der Spek PJ.

Acta Neuropathol Commun. 2018 Sep 12;6(1):91. doi: 10.1186/s40478-018-0591-4. Review.

6.

Bevacizumab and temozolomide in patients with first recurrence of WHO grade II and III glioma, without 1p/19q co-deletion (TAVAREC): a randomised controlled phase 2 EORTC trial.

van den Bent MJ, Klein M, Smits M, Reijneveld JC, French PJ, Clement P, de Vos FYF, Wick A, Mulholland PJ, Taphoorn MJB, Lewis J, Weller M, Chinot OL, Kros JM, de Heer I, Verschuere T, Coens C, Golfinopoulos V, Gorlia T, Idbaih A.

Lancet Oncol. 2018 Sep;19(9):1170-1179. doi: 10.1016/S1470-2045(18)30362-0. Epub 2018 Aug 13.

PMID:
30115593
7.

CMTM4 regulates angiogenesis by promoting cell surface recycling of VE-cadherin to endothelial adherens junctions.

Chrifi I, Louzao-Martinez L, Brandt MM, van Dijk CGM, Bürgisser PE, Zhu C, Kros JM, Verhaar MC, Duncker DJ, Cheng C.

Angiogenesis. 2019 Feb;22(1):75-93. doi: 10.1007/s10456-018-9638-1. Epub 2018 Aug 10.

8.

Heterogeneity within the PF-EPN-B ependymoma subgroup.

Cavalli FMG, Hübner JM, Sharma T, Luu B, Sill M, Zapotocky M, Mack SC, Witt H, Lin T, Shih DJH, Ho B, Santi M, Emery L, Hukin J, Dunham C, McLendon RE, Lipp ES, Gururangan S, Grossbach A, French P, Kros JM, van Veelen MC, Rao AAN, Giannini C, Leary S, Jung S, Faria CC, Mora J, Schüller U, Alonso MM, Chan JA, Klekner A, Chambless LB, Hwang EI, Massimino M, Eberhart CG, Karajannis MA, Lu B, Liau LM, Zollo M, Ferrucci V, Carlotti C, Tirapelli DPC, Tabori U, Bouffet E, Ryzhova M, Ellison DW, Merchant TE, Gilbert MR, Armstrong TS, Korshunov A, Pfister SM, Taylor MD, Aldape K, Pajtler KW, Kool M, Ramaswamy V.

Acta Neuropathol. 2018 Aug;136(2):227-237. doi: 10.1007/s00401-018-1888-x. Epub 2018 Jul 17.

PMID:
30019219
9.

Potential Molecular Signatures Predictive of Lung Cancer Brain Metastasis.

Pedrosa RMSM, Mustafa DAM, Aerts JGJV, Kros JM.

Front Oncol. 2018 May 11;8:159. doi: 10.3389/fonc.2018.00159. eCollection 2018. Review.

10.

Flow cytometry shows added value in diagnosing lymphoma in brain biopsies.

van der Meulen M, Bromberg JEC, Lam KH, Dammers R, Langerak AW, Doorduijn JK, Kros JM, van den Bent MJ, van der Velden VHJ.

Cytometry B Clin Cytom. 2018 Nov;94(6):928-934. doi: 10.1002/cyto.b.21641. Epub 2018 Sep 3.

PMID:
29747221
11.

Prognostic relevance of mutations and copy number alterations assessed with targeted next generation sequencing in IDH mutant grade II glioma.

Wijnenga MMJ, French PJ, Dubbink HJ, Dinjens WNM, Atmodimedjo PN, Kros JM, Fleischeuer R, Dirven CMF, Vincent AJPE, van den Bent MJ.

J Neurooncol. 2018 Sep;139(2):349-357. doi: 10.1007/s11060-018-2867-8. Epub 2018 Apr 16.

12.

Expression-based intrinsic glioma subtypes are prognostic in low-grade gliomas of the EORTC22033-26033 clinical trial.

Gao Y, Weenink B, van den Bent MJ, Erdem-Eraslan L, Kros JM, Sillevis Smitt P, Hoang-Xuan K, Brandes AA, Vos M, Dhermain F, Enting R, Ryan GF, Chinot O, Ben Hassel M, van Linde ME, Mason WP, Gijtenbeek JMM, Balana C, von Deimling A, Gorlia T, Stupp R, Hegi ME, Baumert BG, French PJ.

Eur J Cancer. 2018 May;94:168-178. doi: 10.1016/j.ejca.2018.02.023. Epub 2018 Mar 20.

PMID:
29571083
13.

Breast cancer brain metastasis: molecular mechanisms and directions for treatment.

Pedrosa RMSM, Mustafa DA, Soffietti R, Kros JM.

Neuro Oncol. 2018 Oct 9;20(11):1439-1449. doi: 10.1093/neuonc/noy044.

PMID:
29566179
14.

Approved CAR T cell therapies: ice bucket challenges on glaring safety risks and long-term impacts.

Zheng PP, Kros JM, Li J.

Drug Discov Today. 2018 Jun;23(6):1175-1182. doi: 10.1016/j.drudis.2018.02.012. Epub 2018 Mar 1.

15.

T lymphocytes facilitate brain metastasis of breast cancer by inducing Guanylate-Binding Protein 1 expression.

Mustafa DAM, Pedrosa RMSM, Smid M, van der Weiden M, de Weerd V, Nigg AL, Berrevoets C, Zeneyedpour L, Priego N, Valiente M, Luider TM, Debets R, Martens JWM, Foekens JA, Sieuwerts AM, Kros JM.

Acta Neuropathol. 2018 Apr;135(4):581-599. doi: 10.1007/s00401-018-1806-2. Epub 2018 Jan 19.

16.

Molecular and clinical heterogeneity of adult diffuse low-grade IDH wild-type gliomas: assessment of TERT promoter mutation and chromosome 7 and 10 copy number status allows superior prognostic stratification.

Wijnenga MMJ, Dubbink HJ, French PJ, Synhaeve NE, Dinjens WNM, Atmodimedjo PN, Kros JM, Dirven CMF, Vincent AJPE, van den Bent MJ.

Acta Neuropathol. 2017 Dec;134(6):957-959. doi: 10.1007/s00401-017-1781-z. Epub 2017 Oct 19. No abstract available.

PMID:
29052002
17.

Cgnl1, an endothelial junction complex protein, regulates GTPase mediated angiogenesis.

Chrifi I, Hermkens D, Brandt MM, van Dijk CGM, Bürgisser PE, Haasdijk R, Pei J, van de Kamp EHM, Zhu C, Blonden L, Kros JM, Duncker DJ, Duckers HJ, Cheng C.

Cardiovasc Res. 2017 Dec 1;113(14):1776-1788. doi: 10.1093/cvr/cvx175.

18.

The impact of surgery in molecularly defined low-grade glioma: an integrated clinical, radiological, and molecular analysis.

Wijnenga MMJ, French PJ, Dubbink HJ, Dinjens WNM, Atmodimedjo PN, Kros JM, Smits M, Gahrmann R, Rutten GJ, Verheul JB, Fleischeuer R, Dirven CMF, Vincent AJPE, van den Bent MJ.

Neuro Oncol. 2018 Jan 10;20(1):103-112. doi: 10.1093/neuonc/nox176.

19.

Improving the characterization of endothelial progenitor cell subsets by an optimized FACS protocol.

Huizer K, Mustafa DAM, Spelt JC, Kros JM, Sacchetti A.

PLoS One. 2017 Sep 14;12(9):e0184895. doi: 10.1371/journal.pone.0184895. eCollection 2017.

20.

Antibodies to TRIM46 are associated with paraneoplastic neurological syndromes.

van Coevorden-Hameete MH, van Beuningen SFB, Perrenoud M, Will LM, Hulsenboom E, Demonet JF, Sabater L, Kros JM, Verschuuren JJGM, Titulaer MJ, de Graaff E, Sillevis Smitt PAE, Hoogenraad CC.

Ann Clin Transl Neurol. 2017 Jul 28;4(9):680-686. doi: 10.1002/acn3.396. eCollection 2017 Sep.

Supplemental Content

Support Center